ABSCI CORP (ABSI) Stock Overview
USA - NASDAQ:ABSI - US00091E1091 - Common Stock
ABSI Key Statistics, Chart & Performance
The current stock price of ABSI is 2.61 USD. In the past month the price increased by 1.95%. In the past year, price decreased by -39.58%.
ABSI Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 21.01 | 393.01B | ||
| AMGN | AMGEN INC | 13.09 | 153.65B | ||
| GILD | GILEAD SCIENCES INC | 14.74 | 141.56B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.62 | 98.23B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.97 | 62.75B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 59.45B | ||
| ARGX | ARGENX SE - ADR | 79.48 | 45.09B | ||
| ONC | BEONE MEDICINES LTD-ADR | 5.83 | 39.75B | ||
| INSM | INSMED INC | N/A | 30.60B | ||
| NTRA | NATERA INC | N/A | 24.86B | ||
| BNTX | BIONTECH SE-ADR | N/A | 23.13B | ||
| BIIB | BIOGEN INC | 8.9 | 20.89B |
Related stock screener links
About ABSI
Company Profile
Absci Corp. is the drug and target discovery company harnessing deep learning AI and synthetic biology to expand the therapeutic potential of proteins. The company is headquartered in Vancouver Washington, Washington and currently employs 156 full-time employees. The company went IPO on 2021-07-22. Its Integrated Drug Creation platform combines artificial intelligence (AI) models with a synthetic biology data engine, enabling the design of therapeutics that address challenging therapeutic targets. Its approach leverages a continuous feedback loop between advanced AI algorithms and wet lab validation. Alongside collaborations with pharmaceutical, biotech, tech, and academic companies, the Company is advancing its own pipeline of AI- designed therapeutics. These include ABS-101, an antibody to treat inflammatory bowel disease (IBD), as well as other indications, and ABS-201, for hair regrowth with the potential to redefine treatment possibilities for androgenetic alopecia, commonly known as male and female pattern baldness. The company has four wholly owned, internally developed programs focusing on cytokine biology. Its other pipeline programs include ABS-301 and ABS-501.
Company Info
ABSCI CORP
18105 Se Mill Plain Blvd
Vancouver Washington WASHINGTON US
CEO: Sean McClain
Employees: 157
Phone: 13609491041
ABSCI CORP / ABSI FAQ
What is the stock price of ABSCI CORP today?
The current stock price of ABSI is 2.61 USD. The price decreased by -2.97% in the last trading session.
What is the ticker symbol for ABSCI CORP stock?
The exchange symbol of ABSCI CORP is ABSI and it is listed on the Nasdaq exchange.
On which exchange is ABSI stock listed?
ABSI stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for ABSCI CORP stock?
14 analysts have analysed ABSI and the average price target is 8.29 USD. This implies a price increase of 217.61% is expected in the next year compared to the current price of 2.61. Check the ABSCI CORP stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is ABSCI CORP worth?
ABSCI CORP (ABSI) has a market capitalization of 390.25M USD. This makes ABSI a Small Cap stock.
How many employees does ABSCI CORP have?
ABSCI CORP (ABSI) currently has 157 employees.
What are the support and resistance levels for ABSCI CORP (ABSI) stock?
ABSCI CORP (ABSI) has a support level at 2.43 and a resistance level at 2.75. Check the full technical report for a detailed analysis of ABSI support and resistance levels.
Is ABSCI CORP (ABSI) expected to grow?
The Revenue of ABSCI CORP (ABSI) is expected to grow by 4.13% in the next year. Check the estimates tab for more information on the ABSI EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy ABSCI CORP (ABSI) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of ABSI, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of ABSI, evaluating the profitability, health, valuation and growth aspects
- ABSCI CORP (ABSI) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- ABSCI CORP (ABSI) Sales and EPS estimates to see what analysts future expectations are.
- ABSCI CORP (ABSI) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- ABSCI CORP (ABSI) Insider and Institutional Ownership to learn about the owners and their transactions.
- ABSCI CORP (ABSI) Stock Chart to make your own analysis
- ABSCI CORP (ABSI) Latest news and press-releases to stay up to date.
Does ABSCI CORP (ABSI) stock pay dividends?
ABSI does not pay a dividend.
When does ABSCI CORP (ABSI) report earnings?
ABSCI CORP (ABSI) will report earnings on 2025-11-10, before the market open.
What is the Price/Earnings (PE) ratio of ABSCI CORP (ABSI)?
ABSCI CORP (ABSI) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.94).
What is the Short Interest ratio of ABSCI CORP (ABSI) stock?
The outstanding short interest for ABSCI CORP (ABSI) is 23.34% of its float. Check the ownership tab for more information on the ABSI short interest.
ABSI Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to ABSI. When comparing the yearly performance of all stocks, ABSI is a bad performer in the overall market: 91.08% of all stocks are doing better.
ABSI Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to ABSI. While ABSI seems to be doing ok healthwise, there are quite some concerns on its profitability.
ABSI Financial Highlights
Over the last trailing twelve months ABSI reported a non-GAAP Earnings per Share(EPS) of -0.94. The EPS decreased by -0.64% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -53.98% | ||
| ROE | -65.35% | ||
| Debt/Equity | 0 |
ABSI Forecast & Estimates
14 analysts have analysed ABSI and the average price target is 8.29 USD. This implies a price increase of 217.61% is expected in the next year compared to the current price of 2.61.
For the next year, analysts expect an EPS growth of 8.09% and a revenue growth 4.13% for ABSI